Evaxion Biotech A/S — Form 6-K Summary
Business Context and Reporting Period
Evaxion Biotech A/S, a Danish biotechnology company, filed a Form 6-K as a foreign private issuer. The filing is for the month of June 2024 and was signed June 3, 2024. The filing primarily reports warrant grants and an amendment to the company’s Articles of Association.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material Changes
- On May 1, 2024, the board granted an aggregate of 538,460 warrants to directors, management members, and employees.
- Each warrant permits the holder to subscribe for one ordinary share at an exercise price of $0.40 per share, converted into Danish kroner using the official exchange rate on the exercise date.
- Of the warrants granted, 438,460 vest at a rate of 1/36 per month beginning May 1, 2024, and 100,000 vest at 1/12 per month beginning May 1, 2024.
- Following the grant, 9,461,540 warrants remained available for future grants under the company’s Articles of Association.
- The Articles of Association were amended to reflect the warrant issuances and related provisions. The amended Articles are included as Exhibit 1.1.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operational outlook, risk update, contingencies, or management commentary beyond the warrant grant disclosure.
The warrant grants may result in future share issuance and dilution if exercised. The filing does not state the total potential dilution as a percentage of outstanding shares.
Investor Verification Checklist
- Verify the vesting schedules, exercise-price conversion mechanics, and other terms in Exhibit 1.1 and the amended Articles of Association.
- Determine the number of ordinary shares outstanding and the potential dilution from the 538,460 granted warrants and the 9,461,540 warrants remaining available for future grant.
- Confirm whether the filing date and reporting period—June 3, 2024 and the month of June 2024—align with the requested May 30, 2024 period.
- Review subsequent SEC filings for additional warrant grants, exercises, cancellations, or amendments.